Connection

KEVIN GAREY to Benzimidazoles

This is a "connection" page, showing publications KEVIN GAREY has written about Benzimidazoles.
Connection Strength

0.483
  1. Ridinilazole for the treatment of Clostridioides difficile infection. Expert Opin Investig Drugs. 2019 Apr; 28(4):303-310.
    View in: PubMed
    Score: 0.150
  2. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
    View in: PubMed
    Score: 0.124
  3. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
    View in: PubMed
    Score: 0.122
  4. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.
    View in: PubMed
    Score: 0.054
  5. Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.